Search: WFRF:(Simard Julia F)
> (2010-2014) >
Increased Risk of S...
-
Ludvigsson, Jonas F.,1969-Karolinska Institutet
(author)
Increased Risk of Systemic Lupus Erythematosus in 29,000 Patients with Biopsy-verified Celiac Disease
- Article/chapterEnglish2012
Publisher, publication year, extent ...
-
2012-08-01
-
Journal of Rheumatology,2012
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:oru-55686
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-55686URI
-
https://doi.org/10.3899/jrheum.120493DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:125523974URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)IUS National Institutes of Health (NIH) K23 AR057815-01AISwedish Celiac SocietyFulbright CommissionNational Institutes of Health DK071003 DK057892Alba TherapeuticsNational Institute of Arthritis and Musculoskeletal Diseases K23 AR057815-01A1Ronald F. Kinney Executive Dean for Research Career Development AwardStrategic Research Program in Epidemiology at Karolinska Instituiet
-
Objective: To investigate a possible association between celiac disease (CD) and systemic lupus erythematosus (SLE). Case series have indicated a possible association, but population-based studies are lacking.Methods: We compared the risk of SLE in 29,048 individuals with biopsy-verified CD (villous atrophy, Marsh 3) from Sweden's 28 pathology departments with that in 144,352 matched individuals from the general population identified through the Swedish Total Population Register. SLE was defined as having at least 2 records of SLE in the Swedish Patient Register. We used Cox regression to estimate hazard ratios (HR) for SLE.Results: During followup, 54 individuals with CD had an incident SLE. This corresponded to an HR of 3.49 (95% CI 2.48-4.90), with an absolute risk of 17/100,000 person-years and an excess risk of 12/100,000. Beyond 5 years of followup, the HR for SLE was 2.54 (95% CI 1.57-4.10). While SLE was predominantly female, we found similar risk estimates in men and women. When we restricted our outcome to individuals who also had a dispensation for a medication used in SLE, the HR was 2.43 (95% CI 1.22-4.87). The HR for having 2 records of SLE diagnoses, out of which at least 1 had occurred in a department of rheumatology, nephrology/dialysis, internal medicine, or pediatrics, was 2.87(95% CI 1.97-4.17).Conclusion: Individuals with CD were at a 3-fold increased risk of SLE compared to the general population. Although this excess risk remained more than 5 years after CD diagnosis, absolute risks were low. (First Release Aug 1 2012; J Rheumatol 2012;39:1964-70; doi:10.3899/jrheum.120493)
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Rubio-Tapia, AlbertoDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester MN, United States
(author)
-
Chowdhary, VaidehiDivision of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester MN, United States
(author)
-
Murray, Joseph A.Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester MN, United States
(author)
-
Simard, Julia F.Karolinska Institutet
(author)
-
Karolinska InstitutetDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester MN, United States
(creator_code:org_t)
Related titles
-
In:Journal of Rheumatology: Journal of Rheumatology39:10, s. 1964-19700315-162X1499-2752
Internet link
Find in a library
To the university's database